Loading...
•
Dec 31, 2021
OPKO Health Q4 2021 Earnings Report
OPKO Health's financial performance declined due to decreased COVID-19 testing volume and increased expenses, despite growth in international pharmaceutical businesses.
Key Takeaways
OPKO Health reported a decrease in consolidated total revenues to $401.3 million compared to $494.6 million for the same period in 2020. The company experienced an operating loss of $63.1 million, a net loss of $73.8 million, and a diluted loss per share of $0.11. The decline was primarily due to decreased COVID-19 testing volume and increased investments in BioReference Laboratories' base business and digital health activities.
NGENLA® received regulatory approvals in Europe, Japan, Australia, and Canada.
RAYALDEE® was launched in Germany by Vifor Fresenius Medical Care Renal Pharma.
Topline results were reported from a Phase 2 clinical trial evaluating RAYALDEE as a treatment for symptomatic COVID-19 outpatients.
A definitive agreement was signed for Sema4 Holdings Corp. to acquire GeneDx, Inc.
Revenue by Segment
Forward Guidance
OPKO Health's forward guidance was not explicitly provided in the press release. Therefore, this section summarizes key developments and expectations based on the information available.
Positive Outlook
- Regulatory approvals for NGENLA® in key markets.
- Commercial launch of RAYALDEE® in Germany.
- Potential for Sema4 and GeneDx to become a leading provider of genomic clinical testing.
- Increased demand for COVID-19 PCR tests due to the Omicron variant.
- FDA approval of the Premarket Approval Application (PMA) of the 4Kscore® Test.
Challenges Ahead
- Complete Response Letter from the FDA for somatrogon in the U.S.
- Decrease in COVID-19 testing volume.
- Negative impact on RAYALDEE® sales due to COVID-19 pandemic.
- Operating loss for the fourth quarter of 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...